extremely expensive treatments, is a good candidate for value-based agreements. Take, for example, the high-cost biological drug eteplirsen, which targets the gene responsible for Duchenne muscular dystrophy (DMD). The FDA expedited approval of the drug in 2016 because DMD was a fatal, progressive disease with insufficient treatment options. Approval was granted despite the FDA's advisory committee voting against it and despite slim evidence of efficacy -the pivotal trial, which enrolled just 12 boys, showed very small changes in the surrogate measure used as an outcome.
The agency's decision sent shock waves through the US insurance industry and led to variability in coverage policies. Many companies agreed to pay for the drug, which costs around $300,000 per year, but others initially declined to do so.
In this case, a value-based agreement could have set out a multiyear payment model that would terminate if the effectiveness of the drug failed to persist over the long term. And because such a deal would enable broad access to the therapy, it would in turn generate robust real-world evidence of the treatment's efficacy. Such data could then be used to gain conventional FDA approval. Sarepta Therapeutics in Cambridge, Massachusetts, the company that developed eteplirsen, chose not to enter into value-based agreements for that drug, but it is collaborating with a partner to develop a onetime DMD gene therapy that is expected to be much more expensive. That therapy might present an opportunity to enter into an innovative financing agreement to promote access. Some pharmaceutical companies oppose value-based pricing, questioning whether the approach maximizes shareholder value. It is fair to acknowledge that any solution to improve access to health-care advances should provide a reasonable return to the companies that develop such innovations. It is also appropriate to ask whether treatments for rare conditions should be priced higher to ensure that companies will pursue the development of drugs that will always have a limited market.
Whether or not we choose to acknowledge it, there is a limit to the portion of a country's gross domestic product that can be spent on health care. To balance access and affordability over the long term and ensure that our loved ones can receive the next generation of innovative therapies, payers, pharmaceutical companies and regulatory agencies need to collaborate in a way that benefits all stakeholders. Value-based agreements from the past few years provide a model that could be applied to upcoming gene therapies and other high-cost, innovative treatments. 
